Arcus Biosciences

ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates
ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates
BioSpace
ASCO 2023
Gilead Sciences
Arcus Biosciences
anti-TIGIT
non-small cell lung cancer
domvanalimab
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
Three TIGIT players look to surprise in 2023
Three TIGIT players look to surprise in 2023
EP Vantage
anti-TIGIT
Roche
Merck
Gilead Sciences
Arcus Biosciences
Flag link:
Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease
Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease
Fierce Biotech
Gilead Sciences
Arcus Biosciences
clinical trials
domvanalimab
zimberelimab
non-small cell lung cancer
Flag link:
Opportunities arise for once-spurned partners
Opportunities arise for once-spurned partners
EP Vantage
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Flag link:
Why Arcus Biosciences Stock Is On Fire Today
Why Arcus Biosciences Stock Is On Fire Today
Motley Fool
Arcus Biosciences
Gilead Sciences
anti-TIGIT
etrumadenant
quemliclustat
Flag link:
Arcus declares cryptic interim win for closely watched anti-TIGIT drug, but you'll have to wait for the data
Arcus declares cryptic interim win for closely watched anti-TIGIT drug, but you'll have to wait for the data
Endpoints
Arcus Biosciences
anti-TIGIT
Roche
Flag link:
8 key clinical trials to watch for the rest of 2021
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
clinical trials
Merck
Ridgeback Biotherapeutics
COVID-19
Intellia Therapeutics
transthyretin amyloidosis
Arcus Biosciences
Gilead Sciences
lung cancer
Sanofi
GSK
vaccines
uniQure
Huntington's disease
Mirati Therapeutics
gene editing
Seres Therapeutics
ulcerative colitis
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Arcus nears crunch time for Gilead opt-in
Arcus nears crunch time for Gilead opt-in
EP Vantage
Arcus Biosciences
anti-TIGIT
clinical trials
Gilead Sciences
monoclonal antibodies
Flag link:
Gilead Is Said to Hold Arcus Stake Talks, Spurring 54% Rally
Gilead Is Said to Hold Arcus Stake Talks, Spurring 54% Rally
Bloomberg
Gilead Sciences
Arcus Biosciences
Alphabet
Flag link:
Roche move endorses Iteos’s Tigit widget
Roche move endorses Iteos’s Tigit widget
EP Vantage
Roche
Tigit
tiragolumab
Arcus Biosciences
iTeos Therapeutics
Flag link:
Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials
Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials
BioSpace
Roche
Genentech
Arcus Biosciences
clinical trials
colorectal cancer
pancreatic cancer
AB928
Flag link:
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
CP Wire
AB928
Arcus Biosciences
Taiho Pharmaceutical
oncology
Asia
Japan
Flag link:
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
AB928
Arcus Biosciences
Taiho Pharmaceutical
Flag link:
Arcus Biosciences and Infinity Pharmaceuticals Partner to Evaluate Triple-Combination Therapy in Breast and Ovarian Cancer
Arcus Biosciences and Infinity Pharmaceuticals Partner to Evaluate Triple-Combination Therapy in Breast and Ovarian Cancer
CP Wire
Arcus Biosciences
Infinity Pharmaceuticals
drug development
IPI-549
AB928
AB122
breast cancer
ovarian cancer
Flag link:
Arcus Biosciences and Infinity Pharmaceuticals Partner to Evaluate Triple-Combination Therapy in Breast and Ovarian Cancer
Arcus Biosciences
Infinity Pharmaceuticals
breast cancer
ovarian cancer
Flag link: